A Phase 1 interventional study of AVP-786 and Paroxetine in Drug-drug Interaction, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 1 site in Australia. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-02-18.
Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
To assess steady state pharmacokinetics (PK), safety and tolerability between AVP-786 (deuterated [d6] dextromethorphan hydrobromide [DM]/quinidine sulfate [Q]) and paroxetine and between AVP-786 and duloxetine.
Otsuka Pharmaceutical Development & Commercialization, Inc. is the lead sponsor of 297 studies on the registry; 19 are open to participants now.
Of its 106 completed or terminated interventional studies of FDA-regulated products, 71 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Paroxetine once daily orally Days 1-20. AVP-786 twice daily orally for Days 13 - 20.
Drug: AVP-786 · Drug: Paroxetine
AVP-786 twice daily orally Days 1-20. Paroxetine once daily orally for Days 9 - 20
Drug: AVP-786 · Drug: Paroxetine
Duloxetine twice daily orally Days 1 - 13. AVP-786 twice daily orally Days 6 - 13.
Drug: AVP-786 · Drug: Duloxetine
AVP-786 twice daily orally Days 1 - 13. Duloxetine twice daily Days 9 - 13.
Drug: AVP-786 · Drug: Duloxetine
Drug pages: Deudextromethorphan · Quinidine
Change in plasma concentrations of paroxetine after combined dosing with AVP-786 paroxetine in healthy subjects
Time frame: 20 days
Change in plasma concentration of AVP-786 (parent and metabolites) after dosing in combination with paroxetine.
Time frame: 20 days
Change in plasma concentration of duloxetine after combined dosing with AVP-786
Time frame: 13 days
Change in plasma concentration of AVP-786 after combined dosing with duloxetine.
Time frame: 13 days
Incidence of adverse events (AEs) for AVP-786 and paroxetine
Time frame: 20 days
Incidence of adverse events (AEs) for AVP-786 and duloxetine
Time frame: 13 days
The record gives a start of Jan 2014, a primary completion of Mar 2014 and a completion of Apr 2014. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Deudextromethorphan · Quinidine · Paroxetine · Duloxetine
Otsuka Pharmaceutical Development & Commercialization, Inc. →